drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous antibody-drug conjugate (PADCEV; ASG-22CE) consisting of a monoclonal antibody targeting NECTIN-4 linked to the cytotoxic payload monomethyl auristatin E (MMAE). After binding NECTIN-4 on tumor cells and internalization, the linker is cleaved to release MMAE, a microtubule inhibitor that disrupts tubulin, induces G2/M arrest and apoptosis, and may enable bystander killing and ADCC.
nci_thesaurus_concept_id
C114500
nci_thesaurus_definition
An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.
drug_mesh_term
enfortumab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Enfortumab vedotin is a monoclonal antibody targeting NECTIN-4 linked to the cytotoxic payload MMAE. After binding NECTIN-4 and internalization, the cleavable linker releases MMAE, which inhibits microtubule polymerization, causing G2/M arrest and apoptosis; it may also enable bystander killing and ADCC.
drug_name
Enfortumab vedotin
nct_id_drug_ref
NCT06011954